Afamelanotide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Afamelanotide |
| DrugBank ID | DB04931 |
| Brand Names (EU) | Scenesse |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.87% |
Approved Indication (EMA)
Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | X-linked erythropoietic protoporphyria | 98.87% | DL |
| 2 | autosomal erythropoietic protoporphyria | 98.69% | DL |
| 3 | cutaneous porphyria | 98.36% | DL |
| 4 | erythropoietic protoporphyria | 97.28% | DL |
| 5 | cyclic hematopoiesis | 92.87% | DL |
| 6 | primary hyperoxaluria | 91.33% | DL |
| 7 | X-linked severe congenital neutropenia | 90.67% | DL |
| 8 | autosomal recessive severe congenital neutropenia due to CXCR2 deficiency | 90.08% | DL |
| 9 | cold agglutinin disease | 90.07% | DL |
| 10 | proteinuria | 89.66% | DL |
| 11 | autosomal recessive severe congenital neutropenia due to JAGN1 deficiency | 89.13% | DL |
| 12 | autosomal recessive severe congenital neutropenia due to CSF3R deficiency | 89.11% | DL |
| 13 | adult idiopathic neutropenia | 88.72% | DL |
| 14 | mixed-type autoimmune hemolytic anemia | 88.70% | DL |
| 15 | drug-induced autoimmune hemolytic anemia | 88.64% | DL |
| 16 | isolated congenital growth hormone deficiency | 88.48% | DL |
| 17 | primary CD59 deficiency | 88.47% | DL |
| 18 | progeroid syndrome, Petty type | 88.40% | DL |
| 19 | progeria-short stature-pigmented nevi syndrome | 88.31% | DL |
| 20 | neonatal autoimmune hemolytic anemia | 88.17% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.